Genetics Institute of America (GIA) received IRB approval to expand its Prostate Cancer Study (GH215) utilizing OpsisDx to include: Breast, Ovarian and Lung Cancers. OpsisDx will be used to develop accurate, non-invasive tests for the early detection of these 3 additional cancers.
GIA, empowered by OpsisDx, will be able to screen people for prostate, breast, ovarian, and / or lung cancers once these 4 studies are completed. These tests are expected to detect tumors earlier than liquid biopsies and thereby outperform GRAIL (valued at over $4 billion).
The Entopsis team will continue to support GIA’s efforts of bring impactful tools to patients and physicians. Together, we aim to offer diagnostic tests that better help patients make informed decisions to improve healthspans, not just lifespans.
Full Press Release:
https://www.businesswire.com/news/home/20200721005802/en
Genetics Institute of America Receives IRB Approval to Expand Study to Additional Cancers
- OpsisDxTM Platform Development
- Machine Learning Algorithm
- Study Expanded to Include Breast, Ovarian, Lung Cancers
July 21, 2020 12:47 PM Eastern Daylight Time
MIAMI–(BUSINESS WIRE)–Genetics Institute of America announced today that it has received IRB approval to expand its Prostate Cancer Study (GH215) to include: Breast, Ovarian and Lung Cancers.
“The ability to positively impact patients’ lives is one of the missions of Genetics Institute of America. Bringing additional OpsisDxTM tests to market will help in the care of thousands of patients”Tweet this
Entopsis had earlier entered into a diagnostics commercialization agreement with Genetics Institute of America of Delray Beach, Florida focusing on Prostate Cancer. Genetics Institute of America will develop additional laboratory developed tests (LDT) based on Entopsis’ OpsisDxTM diagnostics platform. The purpose of these tests in Breast, Ovarian and Lung Cancers will be to enhance early detection and diagnosis while reducing unnecessary invasive procedures for patients who are suspected of having cancer.
Genetics Institute of America will run prospective, Institutional Review Board approved, validation studies in its CLIA licensed facility for each cancer type, and launch each laboratory developed test upon successful completion and acceptance of the study.
Entopsis consists of a team of scientists and engineers looking to re-focus the diagnostics industry on early detection and disease prevention with an eye towards improved ‘healthspans’. In 2016, Entopsis was awarded the “Most Disruptive Technology Award” by the Greater Miami Chamber of Commerce.
“We’re pure research scientists, so we’re excited to be working with the team at Genetics Institute of America on this venture,” said Obdulio Piloto, PhD, Co-founder and CEO of Entopsis. “The ability to positively impact patients’ lives is one of the missions of Genetics Institute of America. Bringing additional OpsisDxTM tests to market will help in the care of thousands of patients,” said Holly Magliochetti, CEO and Founder of Genetics Institute of America.
Genetics Institute of America will recruit leading physicians as co-investigators and additional study sites commencing immediately.
About Entopsis
Entopsis was founded in 2011 to pursue the simple idea that an unbiased approach to diagnostics using signatures can be clinically and scientifically useful. The company is predominantly focused in the areas of oncology, autoimmune disorders, and rare diseases. Entopsis is proud to have established strategic academic and industry collaborations with renowned companies and institutions. For more information, please visit http://www.Entopsis.com/.
About Genetics Institute of America
Genetics Institute of America is a national laboratory dedicated to heightening the awareness of early intervention and genetic screening to promote longevity and quality of life outcomes by focusing on DNA, RNA and Proteins. Our modern CLIA laboratory facility in Delray Beach, FL specializes in high complexity molecular testing and contains the most current technology, allowing us to provide leadership in both research and clinical laboratory testing. For more information, please visit http://GenlabUS.com.
Contacts
Holly Magliochetti
media@GenLabUS.com